Théa is a privately owned company solely dedicated to ophthalmology and owned by the Chibret family, based in Clermont-Ferrand, France. The story of Théa’s success begins in the 1870s with Paul Chibret, a military doctor. He was stationed in Tunisia and became interested in trachoma, a disease that would, for him, become a lifelong interest and today forms the background behind the Théa Foundation.
In 1875, Paul Chibret opened a private consultancy in Clermont-Ferrand, Central France.
In 1902, Paul’s nephew, Henry Chibret, founded Laboratoires Chibret and the company developed an entire range of eye drops and ointments.
In 1943, Jean Chibret pioneered the introduction of preservatives into ophthalmic solutions and in imposed an expiry date for their use after opening the glass vials. Ironically, Jean’s son, Henri Chibret eliminated the use of preservatives that his own father had introduced in 1996 following the increasing recognition that Preservative-Free eyecare is better for the tear film, ocular surface and structures within the eye. Find out more
In 1996, Henri Chibret launched the first Preservative-Free multidose bottle, the ABAK®. Under the leadership of Henri, and his nephew, Jean-Frederic, Théa innovation has continued,and today Jean-Frederic ensures that innovation continues to flourish under the flagship Open Innovation programme. Read more.
Paul Chibret is at the centre of pioneering scientific work in ophthalmology. He is the first of five generations of the Chibret family who will dedicate their lives to driving innovation, education and professionalism in ophthalmology.
Henry Chibret continues his uncle’s work, founding Laboratoires CHIBRET.
Henry’s son Jean Chibret opens the world’s biggest documentation centre – the CHIBRET Institute.
Jacques and Henri Chibret both follow in their father’s footsteps launching BIOPHYSIC MEDICAL and Laboratoires TRANSPHYTO.
Laboratoires Théa is launched to sell TRANSPHYO’s products.
Henri Chibret launches the first Preservative-Free, multi-dose bottle. The ABAK® bottle is a high-security, high-technology dispenser which delivers up to 300 drops through a filter which prevents microbial contamination. This leads the way for Preservative-Free formulations and innovative delivery systems. Today, Théa is still highly passionate about Preservative-Free treatments and is dedicated to sharing knowledge with specialists around the world.
Théa Pharmaceuticals is established. Over the last two decades, under the leadership of Henri Chibret, Théa has achieved numerous world firsts and now offers 30 products across a wide range of key therapy areas in ophthalmology.
Théa Pharmaceuticals UK is established.
Launch of Blephasol®,Blephaclean®, Blephagel®, Nutrof® Total, and Hyabak®.
The first comprehensive moist heat therapy for the management of MGD launched.
Théa acquires Mydriasert® for use in cataract surgery.
Azyter, the 1st 3-day topical antibiotic treatment, is launched.
Tiopex® – 1st low dose timolol gel with no quantifiable systemic absorption.
Acquisition of Otrivine Antistin®, Zaditen®, and Voltarol® Optha. Théa Foundation launched.
Théa UK wins Optician Awards 2012 Optical Supplier of the Year Award.
Monopost® – the fist Preservative-Free prostaglandin in single dose format, for the treatment of glaucoma launched along with Aprokam®, the first intracameral antibiotic for prophylaxis of endopthalmitis.
Thealoz® Duo – Unique combination of trehalose and hyaluronic acid without preservatives in an ABAK® bottle for mild to severe dry eye, capitalising on the benefits of Thealoz® and Hyabak®. Also introducing Dexafree®, a Preservative-Free dexamethasone.
Théa Pharmaceuticals supports Moorfields International Glaucoma Symposium.
The first Théa Birmingham Corneal meeting is held, bringing together the leading authorities in the field of cornea. Watch the latest event in Théa Academy.
Mydrane® – 1st intracameral solution for injection to obtain pupil dilation and intraocular anaesthesia directly in the operating room during cataract surgery.
Blephaclean® is launched into hospitals after achieving CE mark.
Softacort®, the first Preservative-Free topical hydrocortisone eye drops for use in cases of mild non-infectious conjunctival inflammation launched.
Blephademodex® launch in response to growing need for clinically proven wipe to combat demodex mite infestation.
Fixapost® – 1st Preservative-Free Latanoprost / Timolol Fixed combination in single-dose – In Europe*.
(*with European marketing authorisation)
Théa UK launches national educational series of webinars freely available to Healthcare Professionals.
Théa UK launches online learning platform, Thea Academy.
Théa UK launches the Blepha EyeBag® – a clinically proven medical device for the treatment of blepharitis, styes, chalazion and meibomian gland dysfunction.
In 2023, TheaLipid(R) was launched for patients suffering from Evaporative Dry Eye.